TY - JOUR
T1 - Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer
T2 - 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease
AU - Bolla, Michel
AU - Neven, Anouk
AU - Maingon, Philippe
AU - Carrie, Christian
AU - Boladeras, Ana
AU - Andreopoulos, Demetrios
AU - Engelen, Antoine
AU - Sundar, Santhanam
AU - van der Steen-Banasik, Elzbieta M.
AU - Armstrong, John
AU - Peignaux-Casasnovas, Karine
AU - Boustani, Jihane
AU - Herrera, Fernanda G.
AU - Pieters, Bradley R.
AU - Slot, Annerie
AU - Bahl, Amit
AU - Scrase, Christopher D.
AU - Azria, David
AU - Jansa, Jan
AU - O’Sullivan, Joe M.
AU - Van Den Bergh, Alphonsus C.M.
AU - Collette, Laurence
AU - Van Den Bergh, A. C.M.
AU - Carrie, C.
AU - Villa, S.
AU - Kitsios, N.
AU - Poortmans, Ph
AU - Bolla, M.
AU - Sundar, S.
AU - Van Der Steen-Banasik, E. M.
AU - Armstrong, J.
AU - Maingon, P.
AU - Bosset, J. F.
AU - Zouhair, A.
AU - Herrera, F. G.
AU - Pieters, B. R.
AU - Slot, A.
AU - Hopkins, K.
AU - Bahl, A.
AU - Ben Yosef, R.
AU - Budach, V.
AU - Boehmer, D.
AU - Scrase, C. D.
AU - Renard, L.
AU - Magrini, S. M.
AU - De Bari, B.
AU - Jansa, J.
AU - Lartigau, E.
AU - Matuszewska,
AU - O’Sullivan, J. M.
AU - the EORTC Radiation Oncology Group
N1 - Publisher Copyright:
Copyright © 2022 American Society of Clinical Oncology. All rights reserved.
PY - 2021/9/20
Y1 - 2021/9/20
N2 - PURPOSE The European Organisation for Research and Treatment of Cancer (EORTC) trial 22991 (NCT00021450) showed that 6 months of concomitant and adjuvant androgen suppression (AS) improves event-(EFS, Phoenix) and clinical disease-free survival (DFS) of intermediate- and high-risk localized prostatic carcinoma, treated by external-beam radiotherapy (EBRT) at 70-78 Gy. We report the long-term results in intermediate-risk patients treated with 74 or 78 Gy EBRT, as per current guidelines. PATIENT AND METHODS Of 819 patients randomly assigned between EBRT or EBRT plus AS started on day 1 of EBRT, 481 entered with intermediate risk (International Union Against Cancer TNM 1997 cT1b-c or T2a with prostate-specific antigen (PSA) $ 10 ng/mL or Gleason # 7 and PSA # 20 ng/mL, N0M0) and had EBRT planned at 74 (342 patients, 71.1%) or 78 Gy (139 patients, 28.9%). We report the trial primary end point EFS, DFS, distant metastasis–free survival (DMFS), and overall survival (OS) by intention-to-treat stratified by EBRT dose at two-sided a 5 5%. RESULTS At a median follow-up of 12.2 years, 92 of 245 patients and 132 of 236 had EFS events in the EBRT plus AS and EBRT arm, respectively, mostly PSA relapse (48.7%) or death (45.1%). EBRT plus AS improved EFS and DFS (hazard ratio [HR] 5 0.53; CI, 0.41 to 0.70; P, .001 and HR 5 0.67; CI, 0.49 to 0.90; P 5 .008). At 10 years, DMFS was 79.3% (CI, 73.4 to 84.0) with EBRT plus AS and 72.7% (CI, 66.2 to 78.2) with EBRT (HR 5 0.74; CI, 0.53 to 1.02; P 5 .065). With 140 deaths (EBRT plus AS: 64; EBRT: 76), 10-year OS was 80.0% (CI, 74.1 to 84.7) with EBRT plus AS and 74.3% (CI, 67.8 to 79.7) with EBRT, but not statistically significantly different (HR 5 0.74; CI, 0.53 to 1.04; P 5 .082). CONCLUSION Six months of concomitant and adjuvant AS statistically significantly improves EFS and DFS in intermediate-risk prostatic carcinoma, treated by irradiation at 74 or 78 Gy. The effects on OS and DMFS did not reach statistical significance.
AB - PURPOSE The European Organisation for Research and Treatment of Cancer (EORTC) trial 22991 (NCT00021450) showed that 6 months of concomitant and adjuvant androgen suppression (AS) improves event-(EFS, Phoenix) and clinical disease-free survival (DFS) of intermediate- and high-risk localized prostatic carcinoma, treated by external-beam radiotherapy (EBRT) at 70-78 Gy. We report the long-term results in intermediate-risk patients treated with 74 or 78 Gy EBRT, as per current guidelines. PATIENT AND METHODS Of 819 patients randomly assigned between EBRT or EBRT plus AS started on day 1 of EBRT, 481 entered with intermediate risk (International Union Against Cancer TNM 1997 cT1b-c or T2a with prostate-specific antigen (PSA) $ 10 ng/mL or Gleason # 7 and PSA # 20 ng/mL, N0M0) and had EBRT planned at 74 (342 patients, 71.1%) or 78 Gy (139 patients, 28.9%). We report the trial primary end point EFS, DFS, distant metastasis–free survival (DMFS), and overall survival (OS) by intention-to-treat stratified by EBRT dose at two-sided a 5 5%. RESULTS At a median follow-up of 12.2 years, 92 of 245 patients and 132 of 236 had EFS events in the EBRT plus AS and EBRT arm, respectively, mostly PSA relapse (48.7%) or death (45.1%). EBRT plus AS improved EFS and DFS (hazard ratio [HR] 5 0.53; CI, 0.41 to 0.70; P, .001 and HR 5 0.67; CI, 0.49 to 0.90; P 5 .008). At 10 years, DMFS was 79.3% (CI, 73.4 to 84.0) with EBRT plus AS and 72.7% (CI, 66.2 to 78.2) with EBRT (HR 5 0.74; CI, 0.53 to 1.02; P 5 .065). With 140 deaths (EBRT plus AS: 64; EBRT: 76), 10-year OS was 80.0% (CI, 74.1 to 84.7) with EBRT plus AS and 74.3% (CI, 67.8 to 79.7) with EBRT, but not statistically significantly different (HR 5 0.74; CI, 0.53 to 1.04; P 5 .082). CONCLUSION Six months of concomitant and adjuvant AS statistically significantly improves EFS and DFS in intermediate-risk prostatic carcinoma, treated by irradiation at 74 or 78 Gy. The effects on OS and DMFS did not reach statistical significance.
UR - https://www.scopus.com/pages/publications/85116958418
U2 - 10.1200/JCO.21.00855
DO - 10.1200/JCO.21.00855
M3 - Article
C2 - 34310202
AN - SCOPUS:85116958418
SN - 0732-183X
VL - 39
SP - 3022
EP - 3033
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 27
ER -